Reports and Briefs on Pharmaceuticals and Healthcare in Asia-Pacific

Published within

« | ... | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | ... | » »|

Type Product title / description Pub Price
Report
Report

Treatment Algorithms: Prostate Cancer

Analysis of current treatment dynamics of prostate cancer. The report assesses uptake rates and order or treatment types across the seven major markets using Datamonitor’s primary physician research of 124 medical oncologists and urologists.

Published By Datamonitor
21 Dec 2011 $4800
Buy
Report
Report

Epidemiology: Migraine – Stable adult population under 50 years will result in stable migraine prevalence

Overview of migraine, disorder definition, and a review of epidemiology literature. This report provides in-depth analysis of patient populations, a 10-year prevalent case forecast, and key patient segments across the seven major markets.

Published By Datamonitor
21 Dec 2011 $2800
Buy
Report
Report

Pharmaceutical Licensing and Alliances in the Asia-Pacific Region

An overview of partnering trends in developed and emerging pharmaceutical markets in the Asia Pacific region from Q3 2010 to Q2 2011, with discussion of the drivers of recent deals and analysis of key deals and agreements in individual countries.

Published By Datamonitor
21 Dec 2011 $4800
Buy

Exclusive online offer: order this report by November 9th and save 20%

To take advantage of this offer enter Promo Code BIO2012 when prompted in the checkout

More information

Report
Report

Biosimilars: Market Entry Strategies

This report provides an analysis of strategies employed by the top 50 pharma companies that are active or plan to enter the biosimilars sector in the future, together with an analysis of biosimilar deal trends among the top 50 pharma companies.

Published By Datamonitor
20 Dec 2011 $2800
Buy
Report
Report

Product Profiles: Epilepsy - Refractory and niche conditions offer potential in otherwise crowded market

In-depth analysis of key brands and pipeline agents indicated for the treatment of epilepsy. Provides a comparative evaluation of clinical and commercial drug attributes to determine competitiveness in the marketplace.

Published By Datamonitor
20 Dec 2011 $6400
Buy
Report
Report

Product Profiles: Insomnia - Orexin receptor antagonists may yet refresh the insomnia market

In-depth analysis of key prescription brands and pipeline agents for the treatment of insomnia. Provides a comparative evaluation of clinical and commercial drug attributes to determine competitiveness in the marketplace.

Published By Datamonitor
19 Dec 2011 $6400
Buy
Report
Report

Market and Product Forecasts: COPD in China – Novel therapies to see patient potential limited by high cost

With a recent boost in sales, Spiriva leads the Chinese COPD market. A number of once-daily monotherapy and combination bronchodilators threaten its dominance in the next 10 years, but the brand’s wide patient potential will insulate its position.

Published By Datamonitor
14 Dec 2011 $6400
Buy
Report
Report

Product Profiles: Osteoporosis - Novel candidates offer the greatest potential

In depth analysis of key brands and pipeline agents indicated for the treatment of osteoporosis. Provides a comparative evaluation of clinical and commercial drug attributes to determine competitiveness in the marketplace.

Published By Datamonitor
14 Dec 2011 $6400
Buy
Report
Report

Product Profiles: Multiple Sclerosis - The race to capture market share intensifies

In depth analysis of key brands and pipeline agents indicated for the treatment of multiple sclerosis. Provides a comparative evaluation of clinical and commercial drug attributes to determine competitiveness in the marketplace.

Published By Datamonitor
12 Dec 2011 $6400
Buy
Report
Report

Cardiovascular and Metabolic Diseases Market Access in China – Managing challenges to harness growing commercial potential

The large number of Chinese CV & metabolic diseases patients brings significant commercial opportunities for Pharma. Plans to expand insurance coverage and improve healthcare infrastructure will enhance therapy access, boosting the market potential.

Published By Datamonitor
09 Dec 2011 $2800
Buy

« | ... | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | ... | » »|

No help is available.